IFNA1 and systemic lupus erythematosus: The new drug anifrolumab inhibits this pathway by targeting the type I IFN receptor (IFNAR1), with studies showing it significantly improves moderate‐to‐severe SLE symptoms, reduces flares, and may protect organs—including the CNS—from IFN‐mediated damage [684].